Safety, Pharmacokinetics, and Antiviral Activity of HGS004, a Novel Fully Human IgG4 Monoclonal Antibody against CCR5, in HIV‐1–Infected Patients | Zendy

Jacob Lalezari | Zendy; Gopal Yadavalli | Zendy; Michael F. Para | Zendy; Gary Richmond | Zendy; Edwin DeJesus | Zendy; Stephen J. Brown | Zendy; Wendy Cai | Zendy; Cecil Chen | Zendy; John Zhong | Zendy; Lu Anne Novello | Zendy; Michael M. Lederman | Zendy; G. Subramanian | Zendy

Open Access

Safety, Pharmacokinetics, and Antiviral Activity of HGS004, a Novel Fully Human IgG4 Monoclonal Antibody against CCR5, in HIV‐1–Infected Patients

Author(s) -

Jacob Lalezari,

Gopal Yadavalli,

Michael F. Para,

Gary Richmond,

Edwin DeJesus,

Stephen J. Brown,

Wendy Cai,

Cecil Chen,

John Zhong,

Lu Anne Novello,

Michael M. Lederman,

G. Subramanian

Publication year - 2008

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/527327

Subject(s) - monoclonal antibody , pharmacokinetics , virology , human immunodeficiency virus (hiv) , antibody , medicine , pharmacology , immunology , biology

HGS004 is a fully human immunoglobulin (Ig) G4 monoclonal antibody against CC chemokine receptor 5 (CCR5) with robust in vitro activity against a diverse panel of CCR5-tropic human immunodeficiency virus type 1 (HIV-1) isolates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research